Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients

Inclusion Criteria:

* a post operation histologically confirmed gastric or esophagogastric junction adenocarcinoma;
* curative D2 or D2+ operation had been performed, and the pathological stage post operation was verified as IIIb or IIIc;
* no adjuvant chemotherapy before or after operation;
* Karnofsky performance status scale ≥ 70;
* prior adjuvant chemotherapy that did not include taxanes and S-1;
* white blood count ≥ 3,500/mm3, absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 100,000/mm3, hemoglobin count ≥ 90 g/dL, serum bilirubin level \< 1.5 of the upper limit of normal (ULN) for the institution, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase ≤ 2.5 ULN, serum albumin ≥ 30g/L, serum creatinine ≤ 1.5 ULN; and
* normal cardiac function with no severe heart disease.

Exclusion Criteria:

Major exclusion criteria were as follows:

* pregnancy or breast feeding;
* past history of allergy to taxanes, platinum and 5-fluorouracil or their analogues;
* radiotherapy for all measurable target lesions;
* obstructive bowel disease;
* past history of other cancers except for cured non-melanoma skin cancer or cervical cancer; and
* concomitant treatment with other anticancer drugs.